Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients
Context Fluvoxamine may have a potential immune-regulatory action and a therapeutic role in severe acute respiratory syndrome-coronavirus (SARS-CoV-2) infection that may prevent progression and/or hospitalization. Aims Trial that compared fluvoxamine versus placebo in nonhospitalized adults with con...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Egyptian Journal of Chest Disease and Tuberculosis |
| Subjects: | |
| Online Access: | http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2023;volume=72;issue=1;spage=40;epage=45;aulast=Ibrahim |
| _version_ | 1797904935632764928 |
|---|---|
| author | Mohammed A Ibrahim Mohammed Shehta |
| author_facet | Mohammed A Ibrahim Mohammed Shehta |
| author_sort | Mohammed A Ibrahim |
| collection | DOAJ |
| description | Context Fluvoxamine may have a potential immune-regulatory action and a therapeutic role in severe acute respiratory syndrome-coronavirus (SARS-CoV-2) infection that may prevent progression and/or hospitalization. Aims Trial that compared fluvoxamine versus placebo in nonhospitalized adults with confirmed SARS-CoV-2 infection (mild and moderate coronavirus disease 2019 cases). Settings and design This is a double-blinded, randomized clinical trial. Patients and methods The study enrolled 162 cases with positive PCR assay for SARS-CoV-2 infection and who were symptomatic within 7 days of the first dose of study medication. Statistical analysis The demographic, clinical, and laboratory data gathered together will be tabulated and statistically analyzed. The statistical analysis of data was carried out using Excel and the SPSS programs statistical package for AQ8 Social Sciences, version 17. Quantitative data were described as median (minimum–maximum). An analysis of the data was carried out to test statistically significant differences between groups. Quantitative data were presented as mean±SD and the Student’s t test was used to compare between two groups. Results In all, 162 patients completed the study; 72 patients were of mild severity; 90 patients were moderate cases and each group was randomized to receive fluvoxamine or placebo besides standard care. In the mild group, no significant difference was recorded while slight significance exists in the moderate severity group. Conclusions Fluvoxamine may have an added value besides the current standard care in reducing the need for hospitalization in outpatient cases, especially pneumonic ones; however, more larger studies are needed. |
| first_indexed | 2024-04-10T09:56:57Z |
| format | Article |
| id | doaj.art-c04477bbb0874fb2a6c43b9d1b73fd85 |
| institution | Directory Open Access Journal |
| issn | 0422-7638 2090-9950 |
| language | English |
| last_indexed | 2024-04-10T09:56:57Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Egyptian Journal of Chest Disease and Tuberculosis |
| spelling | doaj.art-c04477bbb0874fb2a6c43b9d1b73fd852023-02-16T12:15:27ZengWolters Kluwer Medknow PublicationsEgyptian Journal of Chest Disease and Tuberculosis0422-76382090-99502023-01-01721404510.4103/ecdt.ecdt_38_22Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patientsMohammed A IbrahimMohammed ShehtaContext Fluvoxamine may have a potential immune-regulatory action and a therapeutic role in severe acute respiratory syndrome-coronavirus (SARS-CoV-2) infection that may prevent progression and/or hospitalization. Aims Trial that compared fluvoxamine versus placebo in nonhospitalized adults with confirmed SARS-CoV-2 infection (mild and moderate coronavirus disease 2019 cases). Settings and design This is a double-blinded, randomized clinical trial. Patients and methods The study enrolled 162 cases with positive PCR assay for SARS-CoV-2 infection and who were symptomatic within 7 days of the first dose of study medication. Statistical analysis The demographic, clinical, and laboratory data gathered together will be tabulated and statistically analyzed. The statistical analysis of data was carried out using Excel and the SPSS programs statistical package for AQ8 Social Sciences, version 17. Quantitative data were described as median (minimum–maximum). An analysis of the data was carried out to test statistically significant differences between groups. Quantitative data were presented as mean±SD and the Student’s t test was used to compare between two groups. Results In all, 162 patients completed the study; 72 patients were of mild severity; 90 patients were moderate cases and each group was randomized to receive fluvoxamine or placebo besides standard care. In the mild group, no significant difference was recorded while slight significance exists in the moderate severity group. Conclusions Fluvoxamine may have an added value besides the current standard care in reducing the need for hospitalization in outpatient cases, especially pneumonic ones; however, more larger studies are needed.http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2023;volume=72;issue=1;spage=40;epage=45;aulast=Ibrahimclinical trialcoronavirus disease 2019fluvoxaminenonhospitalizednonhypoxemicoutpatientssevere acute respiratory syndrome-coronavirusselective serotonin reuptake inhibitor |
| spellingShingle | Mohammed A Ibrahim Mohammed Shehta Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients Egyptian Journal of Chest Disease and Tuberculosis clinical trial coronavirus disease 2019 fluvoxamine nonhospitalized nonhypoxemic outpatients severe acute respiratory syndrome-coronavirus selective serotonin reuptake inhibitor |
| title | Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients |
| title_full | Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients |
| title_fullStr | Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients |
| title_full_unstemmed | Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients |
| title_short | Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients |
| title_sort | treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients |
| topic | clinical trial coronavirus disease 2019 fluvoxamine nonhospitalized nonhypoxemic outpatients severe acute respiratory syndrome-coronavirus selective serotonin reuptake inhibitor |
| url | http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2023;volume=72;issue=1;spage=40;epage=45;aulast=Ibrahim |
| work_keys_str_mv | AT mohammedaibrahim treatmentwithfluvoxamineinnonhospitalizedcoronavirusdisease2019patients AT mohammedshehta treatmentwithfluvoxamineinnonhospitalizedcoronavirusdisease2019patients |